Battle Card: Libra Therapeutics

🚀 Battle Card: Libra Therapeutics

• Martin Gill, Ph.D., Chief Scientific Officer · 🔗 LinkedIn

• This Libra Therapeutics sales trigger marks a shift toward acceleration of its neurodegenerative pipeline, signaling increased R&D budgets and partnership opportunities. → Source

• Speeding IND-enabling milestones for TRPML1 candidates

• Scaling small-molecule discovery for autophagy-targeting programs

• Primary: Preclinical Development Accelerator → Compress IND-enabling studies by up to 20%

• Expansion: Custom High-Throughput Screening Platform → Expand hit-to-lead throughput by 30%

• HQ: San Diego, CA

• Employees: ≈ 50

• Rev: ≈ $30 M

• Website: libratherapeutics.com

🤼 Competitive Intel

• Charles River — Preclinical CRO
• Unique edge: Broad IND-enabling study portfolio
• Evaluated by VP of Translational Science for toxicology expertise

• Labcorp/Covance — Clinical & Preclinical Services
• Unique edge: Seamless transition from preclinical to clinical
• Evaluated by Head of Clinical Ops for study design alignment

• WuXi AppTec — Integrated R&D Services
• Unique edge: End-to-end small molecule discovery
• Evaluated by CSO for platform consolidation

• Evotec — Drug Discovery Outsourcing
• Unique edge: Deep disease biology partnerships
• Evaluated by Dir. of Research for target validation support

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑compress IND-enabling studies by up to 20%❑
PROOF_METRIC  = ❑20% time reduction in IND-enabling studies❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Martin
COMPANY     = Libra Therapeutics, Inc.
DEPT        = ≈ TBD
SIZE        = ≈50
BOTTLENECK  = scaling small-molecule discovery
EVENT       = Promotes Martin Gill, Ph.D., to Chief Scientific Officer
DETAIL      = Promoted to CSO
PAIN        = delays in IND-enabling milestones for TRPML1 candidates
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251015946971&div=41152219
SIM_CO      = ≈ TBD
WIN_METRIC  = 20% faster IND-enabling studies
NEXT_SIZE   = ≈100
EMP_EST     = ≈50
REV_EST     = ≈$30M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈50-person ≈ TBD

Martin—noticed your ≈ TBD team is ≈50.

That’s when scaling small-molecule discovery slows growth.

We helped ≈ TBD fix this with compress IND-enabling studies by up to 20%.

Result: 20% faster IND-enabling studies.  
Quick call?

PS—next bottleneck hits ≈100.

DM ≤45 words, TONE:
Saw your post about Promoted to CSO — delays in IND-enabling milestones for TRPML1 candidates.  
compress IND-enabling studies by up to 20%. 20% time reduction in IND-enabling studies.  
Quick chat?